.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,980,864

« Back to Dashboard

Claims for Patent: 5,980,864

Title: 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them
Abstract:1,4,7,10-Tetraazacyclodedecane butyltriols of general formula I.sub.A ##STR1## in which R.sup.1 means hydrogen or a metal ion equivalent independent of one another and R.sup.2 means a butyltriol radical as well as their salts with organic or inorganic bases or amino acids are valuable pharmaceutical agents.
Inventor(s): Platzek; Johannes (Berlin, DE), Gries; Heinz (Berlin, DE), Weinmann; Hanns-Joachim (Berlin, DE), Schuhmann-Giampieri; Gabriele (Berlin, DE), Press; Wolf-Rudiger (Berlin, DE)
Assignee: Schering Aktiengellsellschaft (Berlin, DE)
Application Number:07/671,041
Patent Claims: 1. A 1,4,7,10-tetraazacyclododecane butyltriol of formula I.sub.A ##STR8## in which each R.sub.1 is hydrogen or a metal ion equivalent, independent of one another, and

R.sub.2 is 1-hydroxymethyl-2,3-dihydroxypropyl, or a salt thereof with an organic or inorganic base or an amino acid.

2. A compound according to claim 1, wherein all R.sup.1 's are hydrogen atoms.

3. A compound according to claim 1, wherein at least two of substituents R.sup.1 are metal ion equivalents of at least one element of the atomic numbers 21-29, 42, 44 or 57-83 or at least one radionuclide of an element of the atomic numbers 27, 29, 31, 32, 37-39, 43, 49, 62, 64, 70 or 77.

4. 10-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4 ,7,10-tetraazacyclododecane, a compound of claim 1.

5. A compound of claim 1, wherein said metal ion equivalents are of at least one element of atomic numbers 21-29, 42, 44 or 58-70.

6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

7. A method of conducting NMR imaging comprising administering a composition of claim 6 effective therefor.

8. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.

9. A method of conducting NMR imaging comprising administering a composition of claim 8.

10. The gadolinium (III) complex of 10-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10- tetraazacyclododecane.

11. A pharmaceutical composition comprising a compound of claim 10 and a pharmaceutically acceptable carrier.

12. A method of conducting NMR imaging comprising administering a composition of claim 11.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc